10-Q: BioCardia Reports Q3 2024 Results, Provides Update on Clinical Trials and Financial Position

BioCardia's Q3 2024 report highlights progress in clinical trials, a recent capital raise, and ongoing efforts to advance its cell therapy platforms.

Summary

• BioCardia, a clinical-stage company, is focused on developing cell therapies for cardiovascular and pulmonary diseases.
• The company's CardiAMP autologous cell therapy is in pivotal trials for ischemic heart failure and refractory angina.
• Their allogeneic mesenchymal stem cell (MSC) therapy is being developed for ischemic heart failure and acute respiratory distress syndrome (ARDS).
• The company's Helix delivery system is used for minimally invasive delivery of therapies to the heart.
• BioCardia reported a net loss of $1.737 million for the three months ended September 30, 2024, and a net loss of $5.650 million for the nine months ended September 30, 2024.
• The company had cash and cash equivalents of $4.930 million as of September 30, 2024.
• BioCardia completed a public offering in September 2024, raising gross proceeds of $7.2 million.
• The company expects to complete data monitoring for the CardiAMP Heart Failure Trial in Q4 2024, with top-line data expected in Q1 2025.
• They are also advancing the CardiAMP Heart Failure II Trial and the CardiAMP Chronic Myocardial Ischemia Trial.
• BioCardia is also developing its allogeneic MSC therapy for heart failure, with a Phase I/II trial underway.
• The company is actively transitioning to its new FDA-cleared Morph DNA platform for procedures using the Helix delivery system.

Sentiment

Score: 4

Explanation: The document highlights progress in clinical trials and partnerships, but the company's financial situation and dependence on future capital raises create significant uncertainty. The lack of revenue and ongoing losses are concerning, leading to a lower sentiment score.

Positives

• The CardiAMP Heart Failure Trial has completed patient follow-up, moving closer to potential data release and regulatory discussions.
• The FDA approved a protocol amendment for the CardiAMP Heart Failure II Trial, potentially increasing patient eligibility.
• The allogeneic MSC therapy trial has shown no treatment-emergent adverse events in the low dose cohort.
• BioCardia has secured partnerships for its Helix delivery system, potentially generating future revenue.
• The company successfully raised $7.2 million in a public offering, strengthening its financial position.
• The FDA cleared the Morph-DNA product family for market release, expanding the company's commercial offerings.

Negatives

• BioCardia has incurred net losses and negative cash flows since its inception, with an accumulated deficit of $157.8 million as of September 30, 2024.
• The company's cash and cash equivalents of $4.9 million are not sufficient to fund planned expenditures beyond the second quarter of 2025.
• Revenue was $0 for the three months ended September 30, 2024, compared to $357,000 for the same period in 2023.
• Research and development expenses decreased due to the completion of enrollment in the CardiAMP Heart Failure Trial, but the company still faces significant development costs.
• The company's ability to continue as a going concern is dependent on raising additional capital.

Risks

• BioCardia's ability to continue as a going concern is dependent on raising additional capital, which may not be available on acceptable terms.
• The company may need to reduce operating expenses, delay product development, or relinquish rights to technologies if additional funding is not secured.
• The company's therapeutic candidates are subject to regulatory approval, which may not be granted.
• The company's future revenue is dependent on the success of its clinical trials and commercialization efforts.
• The company faces risks associated with the development and commercialization of biopharmaceutical products.
• The company's stock price could be negatively impacted by a failure to maintain compliance with Nasdaq listing requirements.

Future Outlook

BioCardia plans to continue advancing its clinical trials, seek regulatory approvals, and explore partnerships to fund its operations. The company expects to complete data monitoring for the CardiAMP Heart Failure Trial in Q4 2024, with top-line data expected in Q1 2025. They also plan to continue development of their allogeneic MSC therapy and expand commercialization of their Morph-DNA product family. The company anticipates needing additional funding to continue operations beyond the second quarter of 2025.

Management Comments

• Management expects operating losses and negative cash flows to continue through at least the next several years.
• Management believes cash and cash equivalents of approximately $4.9 million as of September 30, 2024 are not sufficient to fund our planned expenditures and meet our obligations beyond the second quarter of 2025.
• Management plans to raise additional capital, potentially including debt and equity arrangements, to finance future operations.
• Management is not aware of any current legal or administrative proceedings that are likely to have an adverse effect on our business, financial position, results of operations, or cash flows.

Industry Context

BioCardia operates in the competitive regenerative medicine space, focusing on cell therapies for cardiovascular and pulmonary diseases. The company's progress in clinical trials and partnerships reflects a broader trend in the industry towards developing innovative therapies for unmet medical needs. The company's focus on minimally invasive delivery systems aligns with the industry's move towards less invasive treatment options.

Comparison to Industry Standards

• BioCardia's focus on autologous and allogeneic cell therapies for heart failure is comparable to other companies in the regenerative medicine space, such as Mesoblast and Vericel, which are also developing cell-based therapies for cardiovascular conditions.
• The company's use of a minimally invasive delivery system, Helix, is similar to other companies developing targeted drug delivery systems, such as those used by companies like Medtronic and Abbott in their cardiovascular device portfolios.
• The company's clinical trial designs, including the use of a Finkelstein-Schoenfeld hierarchical analysis, are consistent with industry standards for evaluating complex outcomes in clinical trials.
• BioCardia's financial position, with ongoing losses and reliance on capital raises, is typical for clinical-stage biotech companies, which often require significant investment before achieving profitability. This is similar to companies like Athersys and Lineage Cell Therapeutics, which are also in the clinical development phase and require ongoing funding.
• The company's revenue model, which includes biotherapeutic delivery partnerships, is a common strategy for biotech companies to generate revenue while developing their own therapeutic candidates. This is similar to companies like Catalent and Lonza, which provide contract development and manufacturing services to other biotech companies.

Legal Proceedings

• The Company may be subject to various claims, complaints, and legal actions that arise from time to time in the normal course of business.
• Management does not believe that the Company is party to any current pending legal proceedings.

Related Party Transactions

• The company has a related party payable for discounts owed to BSLF, L.L.C., an entity owned and controlled by Andrew Blank, Chair of BioCardia's board of directors.

Stakeholder Impact

• Shareholders face the risk of dilution from future capital raises and potential loss of investment if the company is unable to achieve profitability.
• Employees may be impacted by potential cost reductions or delays in product development if the company is unable to secure additional funding.
• Patients may benefit from the company's development of new cell therapies for cardiovascular and pulmonary diseases, but the success of these therapies is not guaranteed.
• Partners may be impacted by the company's financial stability and ability to continue development of its technologies.

Next Steps

• Complete data monitoring for the CardiAMP Heart Failure Trial in Q4 2024.
• Release top-line data from the CardiAMP Heart Failure Trial in Q1 2025.
• Request a meeting with the FDA to discuss the results of the CardiAMP Heart Failure Trial.
• Continue the CardiAMP Heart Failure II Trial and the CardiAMP Chronic Myocardial Ischemia Trial.
• Advance the allogeneic MSC therapy Phase I/II trial.
• Expand commercialization of the Morph-DNA product family.
• Seek additional funding to support operations beyond the second quarter of 2025.

Key Dates

Keywords

cell therapy, cardiovascular disease, heart failure, clinical trials, regenerative medicine, biotherapeutic delivery, ischemic heart failure, refractory angina, mesenchymal stem cells, funding, FDA, Helix delivery system